Urology Times staff

Shilpa Gupta, MD, explains that the toxicities of sacituzumab govitecan and enfortumab vedotin “are not overlapping.”

“We found that treatment-related out-of-pocket costs were 18 times higher for those patients treated with novel hormonal therapies compared to those who were just on standard ADT,” says Daniel D. Joyce, MD.

“I think what becomes important with this is how we need to do our part in terms of not only engaging our non-urology colleagues to help in educating them about these most common problems in urologic conditions, but also really become [advocates] at the medical school level,” says Jessica Kreshover, MD.

The phase 3 PRESTO trial had 3 arms: ADT alone; ADT plus apalutamide; and ADT plus apalutamide plus abiraterone/prednisone.

There are 2 FDA-approved PSMA-PET imaging agents: Gallium 68 PSMA-11 (Ga 68 PSMA-11) and piflufolastat F 18.

In this interview, Howard Goldman, MD, discusses the development of sacral neuromodulation as a treatment for overactive bladder (OAB).

“The management of patients with advanced urothelial carcinoma whose cancer has progressed on immunotherapy presents a unique challenge,” says Moshe Ornstein, MD.

"[Sacral neuromodulation has] changed the treatment of OAB remarkably," says Howard B. Goldman, MD, FACS.

“When we looked at the topics within urology that are covered, either in the preclinical or clinical years, what became very surprising to us is that these highly relevant topics like urologic emergencies, bladder drainage, and erectile dysfunction—less than 1 in 5 students had exposure to during medical school,” says Jessica Kreshover, MD.

“There’s a tremendous amount of work going on right now with PARP inhibitors in the resistant stage, but now also we’re looking at them in the sensitive stage,” says Neal D. Shore, MD.

Catherine Ann Matthews, MD, FACS, FACOG, and John B. Gebhart, MD, MS, preview the upcoming AUGS Clinical Meeting.

“We wanted to compare outcomes between nursing home residents and community-dwelling older adults undergoing surgery for bladder and bowel dysfunction,” explains Anne M. Suskind, MD.

“These data do suggest that [enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda)] is a viable treatment option for cisplatin-ineligible patients,” says Jonathan E. Rosenberg, MD.

“I think the take home message of this study is that there's work to do, and that our efforts in diversity, equity, and inclusion extends broadly beyond simply ensuring that we have the workforce to treat our diverse population, or that urologists are thinking critically and responsibly about the needs of our patients,” says Kevin Koo, MD, MPH.

“PSMA-PET imaging is something that from a clinical practice perspective is rapidly changing and evolving the field of prostate cancer,” says William P. Parker, MD.

“The leadership has really driven this program to be one of the best in the country,” says Casey Kowalik, MD.

“One thing that from the very beginning we talked about is how can we push this forward? How can we think outside the box and take this to the next level to make an impact for our patients?” says Katie Murray, DO, MS.

“There were no serious skin events that occurred on this study, which I think is a credit to the study team that worked with the investigators to manage the manage the toxicity and prevent serious skin reactions,” says Jonathan E. Rosenberg, MD.

“The main finding of the study was that, like…other clinical trial studies in the past, we also found that there was an over representation of non-Hispanic White patients in these trials, and a dramatic under representation of people traditionally and historically underrepresented in clinical trials and in medicine,” says Kevin Koo, MD, MPH.

“There is so much support and so much advocacy to work and create an equitable culture for women in this historically male-dominated field,” says Casey Kowalik, MD.

“A majority of the patients who were referred who had a catheter pre embolization are now catheter free,” says Kimberly Kocour, MD.

Daniel P. Petrylak, MD, discusses results of a post-hoc analysis of the phase 3 ARCHES trial examining outcomes with enzalutamide/ADT treatment intensification in patients with mHSPC and prior ADT based on patients’ baseline PSA level.

Stephen J. Freedland, MD, shares his thoughts on potential new uses for cabazitaxel in the prostate cancer paradigm.

“This concept of adding additional therapy early on is ready for primetime,” says Michael S. Cookson, MD, MMHC.

“We started in 2020 and so far, we’ve had 193 mentors and 126 mentees,” says Micha Cheng, MD, MPH, MS.

“[With] some folks, if you don't accurately risk stratify them, you miss your chance to really build that trust as a provider,” says Neil Mistry, MD, MPH.

The initial results from JAVELIN Bladder 100 supported the FDA approval of avelumab for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma.

“There was about a 32.5% survival advantage for patients with that triple therapy,” says Michael S. Cookson, MD, MMHC.

Stephen J. Freedland, MD, discusses current practice patterns with cabazitaxel in prostate cancer and the potential to use the therapy earlier in treatment sequencing.

The pivotal CARD study compared cabazitaxel to androgen receptor pathway inhibitors in patients with previously treated metastatic castration-resistant prostate cancer.